The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

Anthony G. Marson, Asya M. Al-Kharusi, Muna Alwaidh, Richard Appleton, Gus A. Baker, David W. Chadwick, Celia Cramp, Oliver C. Cockerell, Paul N. Cooper, Julie Doughty, Barbara Eaton, Carrol Gamble, Peter J. Goulding, Stephen J. L. Howell, Adrian Hughes, Margaret Jackson, Ann Jacoby, Mark Kellett, Geoffrey R. Lawson, John Paul LeachPaola Nicolaides, Richard Roberts, Phil Shackley, Jing Shen, David F. Smith, Philip E. M. Smith, Catrin Tudur Smith, Alessandra Vanoli, Paula R. Williamson

    Research output: Contribution to journalArticlepeer-review

    615 Citations (Scopus)

    Abstract

    Summary Background Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term outcomes, quality of life, and health economic outcomes. Methods SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748. Findings For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard ratio [HR] 0·78 [95% CI 0·63–0·97]), gabapentin (0·65 [0·52–0·80]), and topiramate (0·64 [0·52–0·79]), and had a non-significant advantage compared with oxcarbazepine (1·15 [0·86–1·54]). For time to 12-month remission carbamazepine was significantly better than gabapentin (0·75 [0·63–0·90]), and estimates suggest a non-significant advantage for carbamazepine against lamotrigine (0·91 [0·77–1·09]), topiramate (0·86 [0·72–1·03]), and oxcarbazepine (0·92 [0·73–1·18]). In a per-protocol analysis, at 2 and 4 years the difference (95% CI) in the proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine. Interpretation Lamotrigine is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure outcomes and is therefore a cost-effective alternative for patients diagnosed with partial onset seizures.
    Original languageEnglish
    Pages (from-to)1000-1015
    Number of pages16
    JournalLancet
    Volume369
    Issue number9566
    DOIs
    Publication statusPublished - Mar 2007

    Fingerprint Dive into the research topics of 'The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial'. Together they form a unique fingerprint.

    Cite this